HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...

IMPAACT 2017 (MOCHA) week 96 results show long-acting Cabenuva (cabotegravir + rilpivirine) effectively maintained viral suppression in 94.4% of adolescents aged 12 to <18 years Additional paediatric ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...